Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Combined preventive treatment for schistosomiasis, helminths, and malaria in pregnancy
PACTR202609618004600Phase 3Not yet recruiting
- Sponsor
- Centre de Recherches Médicales de Lambaréné
- Start
- Jan 2027
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 3, randomised, double-blind trial of praziquantel, albendazole, mebendazole and sulfadoxine + pyrimethamine in schistosomiasis, Helminthiases and malaria (3 arms), sponsored by Centre de Recherches Médicales de Lambaréné. Primary endpoint: Primary safety endpoint. Planned start Jan 2027; status: not yet recruiting.
02
Drugs
praziquantelalbendazolemebendazolesulfadoxine + pyrimethamine
03
Conditions
schistosomiasisHelminthiasesmalaria
Beyond the preview
Go deeper on PACTR202609618004600.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202609618004600.